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ABSTRACT 43 
Introduction. We performed the first analysis of heart rate variability (HRV) at rest 44 
and exercise under full autonomic blockade on the same subjects, to test the 45 
conjecture that vagal tone withdrawal occurs at exercise onset. We hypothesized 46 
that, between rest and exercise: i) no differences in total power (PTOT) under 47 
parasympathetic blockade; ii) a PTOT fall under 1-sympathetic blockade; iii) no 48 
differences in PTOT under blockade of both ANS branches. 49 
Methods. 7 males (24±3 years) performed 5-min cycling (80W) supine, preceded by 50 
5-min rest during control and with administration of atropine, metoprolol and 51 
atropine+metoprolol (double blockade). Heart rate and arterial blood pressure were 52 
continuously recorded. HRV and blood pressure variability were determined by power 53 
spectral analysis, and baroreflex sensitivity (BRS) by the sequence method. 54 
Results. At rest, PTOT and the powers of low (LF) and high (HF) frequency 55 
components of HRV were dramatically decreased in atropine and double blockade 56 
compared to control and metoprolol, with no effects on LF/HF ratio and on the 57 
normalised LF (LFnu) and HF (HFnu). At exercise, patterns were the same as at rest. 58 
Comparing exercise to rest, PTOT varied as hypothesized. For SAP and DAP, resting 59 
PTOT was the same in all conditions. At exercise, in all conditions, PTOT was lower 60 
than in control. BRS decreased under atropine and double blockade at rest, under 61 
control and metoprolol during exercise. 62 
Conclusions. The results support the hypothesis that vagal suppression determined 63 
disappearance of HRV during exercise.  64 
 65 
 66 
 67 
 68 
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 72 
New & Noteworthy  73 
This study provides the first demonstration, by systematic analysis of heart rate variability 74 
(HRV) at rest and exercise under full autonomic blockade on the same subjects, that 75 
suppression of vagal activity is responsible of the disappearance of spontaneous HRV during 76 
exercise. This finding supports previous hypotheses on the role of vagal withdrawal in the 77 
control of the rapid cardiovascular response at exercise onset. 78 
  79 
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INTRODUCTION 80 
 81 
At exercise start, the characteristics of the heart rate (HR) kinetics under vagal 82 
blockade (12) suggested that sudden withdrawal of vagal tone may occur. This 83 
hypothesis may explain the concomitant sudden increase of cardiac output (13, 25). 84 
Recently, vagal withdrawal was called upon also to explain the early changes in 85 
baroreflex sensitivity upon exercise start (4). If this is so, we should expect that the 86 
amplitude of the rapid HR and cardiac output responses would be greater, the 87 
stronger is the vagal modulation of heart activity at rest.  88 
The experimental evidence, however, is not conclusive under this respect, and 89 
several data seem to contradict the vagal withdrawal hypothesis. For instance, 90 
although we know that resting vagal activation is greater in supine than in upright 91 
position (35, 47, 49), the amplitude of the rapid cardiac output response at exercise 92 
onset was found to be smaller in supine than in upright posture (27; 55). On the other 93 
hand, vagal activity is reduced and sympathetic activation is increased in acute 94 
hypoxia as compared to normoxia (5;18, 23, 57, 58): in spite of this, even in hypoxia 95 
HR determined a large fraction of a significant cardiac output response (26). These 96 
data represent a serious challenge to the vagal withdrawal hypothesis at exercise 97 
onset. 98 
The vagal withdrawal hypothesis at exercise onset may also be tested by 99 
investigating the neural modulation of the heartbeat under pharmacological blockade 100 
of either the vagal or the sympathetic or both branches of the ANS (2, 6, 15, 17, 21, 101 
24, 29, 32, 33, 35, 43, 53). The analysis of spontaneous heart rate variability (HRV) 102 
demonstrated that vagal blockade reduced the total power (PTOT) of HRV, acting on 103 
the reduction of both its high (HF) and low frequency (LF) components. Nevertheless, 104 
little attention was given so far to the analysis of HRV during exercise combined with 105 
pharmacological blockade. Warren et al. (1997) reported that the powers of both the 106 
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LF and the HF peaks were by far lower at exercise than at rest under placebo, but 107 
they did not find differences under vagal blockade with glycopyrrolate; moreover, 108 
esmolol administration provided similar results as placebo. The interpretation of their 109 
results was undermined by the type of drug used and their study was limited by the 110 
fact that they did not analyse blood pressure variability, another important indirect 111 
feature of sympathetic modulation of the cardiovascular system. Polanczyk et al. (42) 112 
showed that atropine and propranolol administration did not vary the spectrum 113 
components of HRV, contrary to their expectations. 114 
 If the vagal withdrawal hypothesis was correct, we should predict that, when 115 
comparing rest and exercise: i) no differences in PTOT, LF and HF under full vagal 116 
blockade would be found; ii) a drastic fall in PTOT, LF and HF under selective 1-117 
sympathetic blockade would occur; iii) no differences in PTOT, LF and HF under 118 
simultaneous blockade of the two branches of the ANS would appear. Moreover, we 119 
expected that arterial blood pressure variability would not follow the same pattern of 120 
response as HRV, because the former reflects more the peripheral sympathetic 121 
vascular modulation than the central cardiac modulation. 122 
These predictions were tested in the present study, the aim of which was to 123 
investigate the effects of vagal blockade, of selective 1-sympathetic blockade and of 124 
simultaneous blockade of both branches of the ANS, at rest and during exercise, on 125 
HRV and blood pressure variability.  126 
 127 
 128 
METHODS 129 
 130 
Participants 131 
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Seven healthy non-smoking young participants volunteered for the 132 
experiments. They were (mean ± SD) 24.3 ± 2.6 years old, 181.2 ± 3.1 cm tall and 133 
weighed 78.9 ± 6.1 kg. Exclusion criteria were: presence of history of 134 
cardiopulmonary disease and regular use of drugs at the time of the study. 135 
Participants were instructed to avoid caffeine consumption 24 hours before the visit 136 
and to refrain from performing strenuous exercise the day before testing. 137 
All participants were preliminarily informed on the design and risks 138 
associated with the experiments and they signed a written informed consent. The 139 
study was conducted in accordance with the Declaration of Helsinki, and the protocol 140 
was approved by the local institutional ethical committee.  141 
 142 
Protocol and measurements 143 
The experiments were carried out in the Clinical Physiology Laboratory of the 144 
University of Geneva, Switzerland. The volunteers reported to the laboratory on four 145 
different days, with at least a 48-hour recovery between visits. Experiments were 146 
performed in supine posture, in order to reduce potential mechanical effects related 147 
to the remarkable sudden increase in venous return at exercise start upright. After 148 
instrumentation, a 20-gauge catheter was placed in the antecubital vein of the right 149 
arm to administer drugs. A unique 5-min monitoring at rest preceded a series of three 150 
5-min constant-load leg exercises, on cycle ergometer, at 80 watts, to avoid lactate 151 
threshold. Between repetitions a 5-min recovery was administered.  152 
For the entire duration of the protocol, we obtained continuous recordings of 153 
the electrocardiogram (Elmed ETM 2000, Heiligenhaus, Germany), and the arterial 154 
pulse pressure profiles, obtained at a fingertip of the left arm by means of a non-155 
invasive cuff pressure recorder (Portapres, FMS, Amsterdam, The Netherlands).  156 
The R-R interval (RR) and its reciprocal, HR, were computed beat-by-beat. 157 
Systolic and diastolic blood pressure (SAP and DAP, respectively) values were 158 
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obtained from each pulse pressure profile, using the Beatscope® software package 159 
(FMS, Amsterdam, The Netherlands). Beat-by-beat mean arterial pressure (MAP) 160 
was computed as the integral mean of each pressure profile, using the same 161 
software package. Breathing frequency was also calculated from the 162 
electrocardiogram plot. 163 
 164 
All the signals were digitalized in parallel by a 16-channel A/D converter 165 
(MP150, Biopac Systems, Goleta CA, USA) and stored on a computer. The 166 
acquisition rate was 400 Hz. 167 
The protocol was performed under four experimental conditions, 168 
administered in random order: i) control, i.e. with placebo infusion, ii) 169 
parasympathetic blockade with atropine administration, ii) selective β1-adrenergic 170 
blockade with metoprolol administration, and iv) double blockade of both branches of 171 
the ANS with simultaneous atropine and metoprolol administration. 172 
 173 
Drug administration 174 
Parasympathetic blockade was achieved by administering atropine in a 175 
single 0.04 mg/kg dose (mean 3.06 ± 0.23 mg, range 2.7 – 3.4 mg), which was used 176 
in previous studies to attain full vagal blockade (14, 17, 31, 59). The half-life of a 177 
single atropine dose is 180 minutes (52) so that, blockade was maintained during the 178 
entire duration of each experiment. 179 
The 1-adrenergic blockade was attained by using metoprolol tartrate 180 
(Loprésor, Novartis, Switzerland). After an initial bolus of 15 mg, metoprolol tartrate 181 
was continuously infused in an antecubital vein at a rate of 45 mg per hour, by 182 
means of an infusion pump. The efficacy of adrenergic blockade along time was 183 
evaluated on a separate session, by analysing the heart rate response following 184 
isoprenaline injection, as previously described (14). The correct metoprolol 185 
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maintenance dose was identified as the dose ensuring an 80% reduction of the HR 186 
response to isoprenaline for the entire protocol duration.  187 
For the experiments with double, simultaneous sympathetic and 188 
parasympathetic blockade, the same atropine and metoprolol dose and 189 
administration procedure described here above were applied. 190 
 191 
Data treatment 192 
After construction of the time series of RR, SAP and DAP from the continuous 193 
recordings of electrocardiogram and pulse pressure profiles, Fast Fourier Transform 194 
(FFT) was used to evaluate spontaneous variability of RR, SAP and DAP (35). The 195 
data length used was 5 minutes at rest and 3 minutes at exercise. In the latter case, 196 
one repetition, that with the most stable and cleanest trace, was analysed. The total 197 
power (PTOT) (0.0-0.5 Hz) of RR, SAP and DAP variabilities, corresponding to 198 
variance, was initially computed. Subsequently, the powers and frequencies of LF 199 
(0.03–0.14 Hz) and HF (0.15–0.5 Hz) components of the power spectrum were 200 
computed and expressed in absolute units (ms2). The very low frequency component 201 
was neglected. The LF/HF ratio was also calculated. Normalized LF and HF (LFnu 202 
and HFnu, respectively) were computed as: 203 
LF×100
Ptot−VLF
   (1) 204 
and expressed in normalized units (28).  205 
The spontaneous baroreflex sensitivity (BRS, expressed in ms mmHg-1) was 206 
estimated from SAP and RR by means of the sequence method (3). Sequences of at 207 
least three heartbeats, corresponding to an increase or decrease in SAP and 208 
identifying a consensual change in RR interval, were selected. Linear regression 209 
analysis was applied on these sequences and the calculated slope was retained. 210 
BRS was then calculated as the mean of the slopes of all sequences per each 211 
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participant in each condition. Only sequences showing a coefficient of determination 212 
of at least 0.85 were analysed. 213 
Spectral analysis and BRS were performed on Matlab® environment as previously 214 
described (41). Breathing Frequency was calculated with the ECG-Derived-215 
Respiration method used by Moody et al. (30). 216 
 217 
 218 
Statistics 219 
Data are reported as group means ± standard deviation. The effects of 220 
medication and exercise type on the main outcomes were analysed by 2-way 221 
ANOVA for repeated measurements. When applicable, a Tukey post-hoc test was 222 
used to locate significant differences. Differences were considered significant if 223 
p<0.05. All data were analysed with Statistica 12 © (StatSoft, Inc., Tulsa, OK). 224 
 225 
RESULTS 226 
All participants successfully completed the study maintaining a normal sinus 227 
beat along the four experimental conditions (no arrhythmic beats were observed). 228 
The mean values of measured and calculated variables at rest and during exercise 229 
for all conditions are reported in Table 1. At rest, in control condition, HR was 62.7 ± 230 
8.5 min-1. Under sympathetic blockade, no significant differences with respect to 231 
control were observed. Under atropine, it was significantly higher than in control and 232 
under metoprolol. Under double blockade, it was higher than in control and under 233 
metoprolol, but lower than under atropine. During exercise, in control condition, HR 234 
was 105.0 ± 12.4 min-1, and was higher under metoprolol, atropine and double 235 
blockade than in control. With respect to the corresponding values at rest, HR during 236 
exercise increased in all conditions except double blockade.  237 
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At rest, in control condition SAP was 112.0±9.5 mmHg and DAP was 55.0±9.6 238 
mmHg. With respect to control, no differences were observed for either SAP or DAP 239 
with any investigated pharmacological treatment, although with double blockade, 240 
DAP tended to be higher than in control and was significantly higher than under 241 
metoprolol. MAP was 74.0±8.6 mmHg in control and did not differ in the three 242 
investigated pharmacological conditions, except that it was higher under double 243 
blockade than with metoprolol. Breathing frequency was 0.23±0.06 Hz in control and 244 
did not change in the three conditions. At exercise, in control condition, SAP was 245 
138.5±17.5 and DAP was 60.9±7.5 mmHg. With respect to control, SAP was 246 
significantly lower under the three pharmacological conditions. No differences were 247 
observed for DAP. MAP was 86.8±9.9 mmHg in control and did not vary significantly 248 
among conditions. With respect to the corresponding values at rest, MAP during 249 
exercise was higher only in control. Breathing frequency was 0.42±0.07 Hz in control 250 
and did not change in the three other conditions. 251 
HRV data are shown in Table 2. Examples of HRV spectra are shown in 252 
Figure 1. At rest, with respect to control, PTOT was not affected by metoprolol 253 
administration, but it was largely and significantly decreased under atropine and 254 
double blockade, due to drastically lower values of both LF and HF powers. No 255 
differences between atropine and double blockade were found. The same was the 256 
case at exercise, although the difference were much smaller than at rest, because, 257 
when moving from rest to exercise, PTOT was drastically reduced in control and 258 
under metoprolol. No differences for LF and HF powers between sympathetic 259 
blockade and control, or between atropine and double blockade, were observed.  260 
At rest, the LF/HF ratio at rest was unaffected by drug treatment, the only 261 
significant difference being between atropine and double blockade. The same was 262 
the case for LFnu. No differences were observed concerning HFnu. At exercise, the 263 
LF/HF ratio did not differ under metoprolol or atropine with respect to control, but it 264 
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was lower under double blockade than in control and in the other pharmacological 265 
conditions. The same was the case for LFnu. Coherently, HFnu was higher in double 266 
blockade than in any other condition. 267 
All data concerning spontaneous SAP and DAP variability are shown in Table 268 
3. At rest, concerning SAP, no differences among conditions were observed for PTOT. 269 
Concerning the LF power, no differences between sympathetic blockade and control 270 
were found, but it was lower under atropine and double blockade than in control and 271 
sympathetic blockade. The HF power in atropine and double blockade was lower 272 
than in control and under metoprolol, although for the latter the level of significance 273 
was not attained. During exercise, PTOT was lower in all three investigated 274 
pharmacological conditions than in control, but no differences among conditions were 275 
observed for both the LF and the HF powers. In control and under atropine, the LF 276 
power was higher at exercise than at rest. The LF/HF ratio was unchanged in all 277 
conditions.  278 
At rest, concerning DAP, no changes in PTOT were found in any 279 
pharmacological condition with respect to control. The HF power did not vary among 280 
conditions, while the LF power was lower in atropine and double blockade than in 281 
control. The LF/HF ratio was lower in all conditions than in control. During exercise, 282 
there were no significant differences among conditions or with respect to the same 283 
condition at rest. 284 
The BRS values at rest and exercise are shown in Figure 2. At rest, BRS was 285 
significantly lower under atropine and under double blockade than in control and 286 
under sympathetic blockade, which in turn did not differ between them. During 287 
exercise, BRS under atropine and double blockade was lower than in control and 288 
under sympathetic blockade. BRS was lower at exercise than at rest in all conditions 289 
except double blockade. 290 
 291 
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DISCUSSION 292 
 293 
The analysis of spontaneous heart rate variability at rest showed that: 1. 294 
atropine administration drastically reduced PTOT, due to the fall of both LF and HF 295 
powers, with respect to control; 2. simultaneous double blockade with atropine and 296 
metoprolol provided the same results as atropine administration only; 3. metoprolol 297 
administration had no effects on heart rate variability.  298 
When moving from rest to exercise, our results showed that: 1. no differences 299 
in PTOT, LF and HF appeared under atropine and under simultaneous atropine and 300 
metoprolol administration with respect to rest; 2. PTOT, and the LF and HF powers, 301 
were decreased by the same extent under metoprolol as in control. However, during 302 
exercise, PTOT, and the LF and HF powers were lower under atropine and double 303 
blockade than in control or with metoprolol.  304 
These results are in line with the predictions made, and thus do not allow 305 
refutation of the vagal withdrawal hypothesis, but rather reinforce it. Although, taken 306 
separately, similar consistent results can be found in the previous literature (2, 6, 8, 307 
10, 11, 15, 17, 21, 24, 29, 32, 33, 35, 43, 44), this is the first time that a complete 308 
picture of the role of the autonomic nervous system in determining heart rate 309 
variability in rest and exercise was obtained. 310 
 311 
Heart rate variability 312 
The significant increase in HR after atropine administration is in line with 313 
previous studies (9, 21, 22, 48, 50) and was opposed by the observation that, after 314 
metoprolol administration, despite a slight decrease, HR did not change significantly 315 
compared to control. These results were similar in size to those obtained in a 316 
previous study with the same drug (48). However, they are at variance with those of 317 
other studies, carried out in upright posture, showing a significant HR reduction at 318 
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rest with beta-blockade (11, 14, 15, 19). In supine posture, the predominance of 319 
vagal modulation of HR (20, 35) may explain the lack of HR changes with metoprolol.  320 
Concerning HRV, metoprolol failed in changing PTOT, LF and HF at rest, 321 
indicating that a selective blockade of cardiac -adrenergic receptors has no effects 322 
on spontaneous HR oscillations. This suggests that the sympathetic outflow to the 323 
heart may not be the main determinant of HRV, although the PTOT values under 324 
double blockade appear lower (just a tendency) than under atropine. These results 325 
for PTOT, although in agreement with those of some previous studies (15, 53), are in 326 
contrast with those by Cogliati et al. (11), who showed an increase in PTOT under 327 
atenolol, supporting the idea that the pattern was mostly due to an increase in the HF 328 
peak. This finding suggested stronger cardio-respiratory coupling under atenolol than 329 
in control. Comparable results were obtained by others (40) using propranolol.                                                                                          330 
Spontaneous HR oscillations were almost suppressed after atropine 331 
administration, as previously found (8, 15, 21, 29, 32, 33, 53), supporting the notion 332 
that parasympathetic outflow to the heart is the major determinant of HRV in resting 333 
humans. This was so also under simultaneous sympathetic and vagal blockade, 334 
indicating that suppression of the parasympathetic modulation of the heartbeat was 335 
the most important determinant of the present results. Breathing frequency did not 336 
change in the three conditions, being obviously higher at exercise than at rest. This 337 
implies that changes in HF power were not due to any change in breathing 338 
frequency.                                                                                                                                                                                                                        339 
Coherently, in the present study, passing from rest to exercise implied a large 340 
fall in LF and HF powers in control and under metoprolol. Conversely, under atropine 341 
and double blockade, in which a suppression of the vagal modulation of HR was 342 
obtained already at rest, no changes were found at exercise with respect to rest. 343 
These results demonstrate that the well-known fall of HRV, which is usually observed 344 
during exercise (37), is essentially a consequence of the withdrawal of the vagal 345 
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outflow to the heart occurring at exercise onset (12, 25), as hypothesized. As such, 346 
our results suggest that vagal withdrawal is incomplete at the investigated powers, 347 
because the LF and HF powers during exercise were still higher in control than with 348 
atropine or double blockade, the two conditions in which a full blockade of muscarinic 349 
receptors was attained. On the other hand, the fact that passing from rest to exercise 350 
generated comparable results with metoprolol as in control, is coherent with the 351 
reported decrease of the LF peak in humans (37, 39). These data are in contrast with 352 
the generally accepted notion that, during exercise, the degree of sympathetic 353 
activation increases (46, 54) and the modulation of the heartbeat by the sympathetic 354 
efferents becomes predominant (38, 45). This may mean that HRV in exercise does 355 
not reflect the degree of ongoing sympathetic activation.  356 
When we look at the normalized variables at rest, none of the investigated 357 
drugs could change the LF/HF significantly with respect to control: this reflects the 358 
finding that the effects of drug administration on the LF and HF powers at rest were 359 
of the same size. In contrast, during exercise, there was a tendency toward a lower 360 
HF power than LF power. Yet this tendency, though not significant, was such as to 361 
provide, at exercise compared to rest, significantly lower HFnu values in control and 362 
under sympathetic blockade (only a tendency in A and in DB). Consequently, LF/HF 363 
ratio resulted higher at exercise than at rest, at least in these two cases.  364 
In the context of the present hypothesis, this would suggest that the 365 
withdrawal of vagal tone at exercise onset might have had greater effects on the HF 366 
than on the LF component of HRV. Alternatively, the relative increase of the LF 367 
component of RR variability may suggest an increase of the cardiac sympathetic 368 
modulation. Nevertheless, LFnu in double blockade was significantly lower and HFnu 369 
significantly higher than in control, despite the lack of differences in the LF/HF ratio. 370 
This may be due to the non-autonomic effect of an increase in ventilation that is 371 
reflected on HRV through changes in venous return during exercise. A similar 372 
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condition can be observed in a neurodegenerative disease such as the pure 373 
autonomic failure. This condition is characterized by both a cardiac sympathetic and 374 
parasympathetic denervation leading to PTOT values mimicking high dosage atropine 375 
administration (16), in which a HF component of HRV, non-autonomic in origin, is 376 
present (39). These apparently contradictory results prevent us from arriving at clear-377 
cut conclusions concerning the mechanisms at the basis of relative powers in this 378 
study.  379 
 380 
Blood pressure variability 381 
Arterial blood pressure at rest was unaffected by drug administration. The fact 382 
that atropine did not act on systemic blood pressure, in agreement with previous 383 
studies (15, 21), is coherent with the notion that there is no cholinergic innervation in 384 
most regional circulations. On the other hand, metoprolol is a selective blocker of 1-385 
adrenergic receptors that are expressed specifically in the heart, not in arterioles, so 386 
that it is not expected to induce changes in blood pressure. 387 
 Coherently, SAP variability was much less affected by atropine and double 388 
blockade than HRV. According to Zhang et al. (61), who investigated spontaneous 389 
blood pressure variability under ganglionic blockade with Trimethaphan, the HF peak 390 
of blood pressure variability is mediated by mechanical effects due to the breathing 391 
cycle and cardiac filling: if this is so, one would not expect effects of any of the drugs 392 
used in this study on the HF power for blood pressure. In fact, the changes in HF 393 
power due to drug administration in the present study were much smaller than for 394 
HRV, although significant under atropine and double blockade. Zhang et al. (61) also 395 
attributed the LF power of blood pressure variability to either sympathetic activity or 396 
intrinsic vascular rhythmicity: if this is so, no changes in LF were to be found with 397 
atropine, metoprolol or double blockade: in fact, we found much smaller differences 398 
in LF power due to drug administration for blood pressure variability than for HRV. 399 
Downloaded from www.physiology.org/journal/jappl by Alessandra Adami (131.128.072.082) on October 13, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
16 
 
Yet these changes were consensual with those of HF power, being significant under 400 
atropine and double blockade. These effects might have been an indirect 401 
consequence of the role that the autonomic nervous system may play in modulating 402 
the dynamic relationship between HRV and blood pressure variability (7, 61), with an 403 
involvement of its parasympathetic branch.  404 
Most remarkable are the differences observed when passing from rest to 405 
exercise: the LF power for SAP increased in control, as expected (37, 39), and with 406 
atropine, but not with metoprolol and in double blockade. This indicates that the 407 
increase in LF power for SAP may be a consequence of increased sympathetic 408 
modulation during exercise. No effects were observed under any drug on the HF 409 
power: this means that the HF power of SAP is independent of the activity of the two 410 
branches of the ANS. The lack of exercise effects on HF power under drug 411 
stimulation explains why the PTOT did not differ significantly at exercise with respect 412 
to rest under atropine.  413 
DAP variability was unaffected by drug administration: this suggests that the 414 
exercise effect on the LF power of SAP, related to a selective blockade of 1 415 
adrenergic receptors, is mediated by a central (cardiac) rather than a peripheral 416 
(arteriolar muscle vasodilation) action of the sympathetic branch of the ANS. 417 
 418 
Baroreflex sensitivity 419 
At rest, BRS was drastically lower under atropine and double blockade than in 420 
control. This observation was consistent with what we observed for the LF peak of 421 
blood pressure variability: reduced under atropine and double blockade, unchanged 422 
under metoprolol, with respect to control. Coherently, when comparing rest with 423 
exercise in a given condition, BRS decreased in control and under metoprolol, but did 424 
not change under atropine and double blockade. These results on BRS appear in 425 
agreement with previous observations (1, 11, 56). Bringard et al. (4) postulated that 426 
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BRS is mainly modulated by the parasympathetic efferent branch on the ANS. These 427 
data support this hypothesis. Muscarinic receptors do not modulate smooth muscle 428 
tone in most arterioles, including those of skeletal muscles. Thus, the 429 
parasympathetic effect on arterial blood pressure variability indexes must be indirect. 430 
Based on the present results, we speculate that baroreflexes may participate in the 431 
modulation of the LF power of arterial blood pressure. The reduction of BRS 432 
observed during exercise (51) support the idea of alfa-index changes as previously 433 
reported (36). In the present study, the BRS reduction at exercise was observed only 434 
in control and with metoprolol, but not with atropine and double blockade. This finding 435 
reinforces the notion that withdrawal of vagal tone is responsible for the fall of BRS at 436 
exercise onset (4, 34). Coherently, no differences in BRS among the four 437 
investigated conditions were observed during exercise. 438 
 439 
Study limitations 440 
A limitation of this study may be suggested by the lack of differences between 441 
control and metoprolol, as this may also suggest that the 1-adrenergic blockade 442 
might have been incomplete. It is of note, however, that we used the same dose and 443 
followed the same procedure of metoprolol administration as in a previous study (14) 444 
in upright posture, which showed a significant resting HR decrease both in normoxia 445 
and in acute hypoxia at rest as at exercise. Moreover, we observe that the 446 
isoprenaline test provided unambiguous evidence of quasi-complete 1-adrenergic 447 
blockade.  448 
Another possible limiting factor is related to the fact that HR rate differed 449 
remarkably among conditions. This may affect the HRV indexes in time domain per                                                                                                                                                                                                                                                                                         450 
se (59), thus possibly undermining the relation to the action of the autonomic nervous 451 
system. 452 
 453 
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CONCLUSION 454 
The results of this study support the tested hypothesis that vagal suppression 455 
is responsible of the disappearance of the spontaneous HRV during exercise. The 456 
observed effects on arterial blood pressure variability are indirectly related to the 457 
action of the administered drugs, supporting the notion that blood pressure and HRV 458 
are only partially-associated phenomena, possibly controlled by different 459 
physiological mechanisms 460 
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 636 
Table 1: Mean steady state values for the cardiovascular variables monitored during rest (R) 637 
and exercise (E) in the four experimental conditions: Control, Atropine, Metoprolol, and 638 
Double Blockade. 639 
 640 
Values are means ± SD. HR: heart rate; RR: R-R interval; SAP: systolic arterial pressure; 641 
DAP: diastolic arterial pressure; MAP: mean arterial pressure; BRS: spontaneous baroreflex 642 
sensitivity. BF: breathing frequency. 643 
N=7; 2-way ANOVA for repeated measurements; p<0.05; *: significantly different from 644 
Control. #: significantly different from Atropine. §: significantly different from Double 645 
Blockade. In bold: Exercise significantly different from Rest.  646 
Measured 
variables 
 Control Metoprolol Atropine Double 
Blockade 
HR (min
-1
) 
R 62.67±8.47 59.58±7.11
#§ 111.17±17.75*§ 93.71±5.48* 
E 105.04±12.39 93.53±8.17
# 135.04±20.56* 103.19±8.06# 
RR (ms) 
R 985.3 ± 185.7 1017.7 ± 104.4
# 548.6 ± 79.5 *§ 642.1 ± 38.2 * 
E 577.9 ± 66.2 645.3 ± 51.3
# 455.9 ± 89.3* 584.2 ± 41.1# 
SAP (mmHg) 
R 111.97±9.52 109.75±13.89 112.96±11.83 119.48±14.29 
E 138.51±17.53 113.58±15.21* 108.73±15.94* 107.70±14.76* 
DAP (mmHg) 
R 54.95±9.64 48.96±10.81
§ 60.95±9.10 66.16±8.43 
E 60.94±7.48 53.35±13.55 54.21±7.72 54.34±6.92 
MAP (mmHg) 
R 73.95±8.59 69.22±10.42
§ 78.28±7.76 83.93±7.78 
E 86.79±9.88 73.42±13.53 72.58±10.03 72.13±9.41 
BRS (ms 
mmHg
-1
) 
R 25.74 ± 11.28 27.42 ± 8.51
# 2.17 ± 1.06 *§ 3.00 ± 0.92 * 
E 2.59 ± 1.76 3.17 ± 0.62 
# 0.85 ± 0.31* 2.13 ± 0.44 
BF (Hz) 
R 0.23 ± 0.06 0.21 ± 0.06 0.29 ± 0.04 0.23 ± 0.07 
E 0.42 ± 0.07 0.39 ± 0.04 0.40 ± 0.04 0.41 ± 0.07 
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Table 2: Mean and standard deviations of all parameters calculated by means of heart rate 647 
variability in the four investigated conditions: Control, Atropine, Metoprolol, and Double 648 
Blockade. 649 
Heart Rate variability 
 
Control Metoprolol Atropine Double blockade 
ABSOLUTE 
VALUES 
     
PTOT (ms2Hz
-1
) 
R 6351.4 ± 4476.4 7883.2 ± 5965.9 22.5 ± 13.8*● 12.9 ± 4.9*● 
E 185.4 ± 77.1 93.6 ± 30.9* 10.1 ± 3.3*● 14.8 ± 4.7*● 
LF (ms2Hz
-1
) 
R 1717.5 ± 1290.6 2711.9 ± 2061.8 1.5 ± 1.2*
● 1.1 ± 0.5*● 
E 40.6 ± 29.3 41.3 ± 29.3 1.7 ± 1.4*
● 1.6 ± 1.5*● 
HF (ms2Hz
-1
) 
R 1441.0 ± 1296.1 2552.3 ± 2245.0 0.9 ± 0.5*
● 2.6 ± 0.8*● 
E 10.8 ± 7.8 11.2 ± 9.2 0.3 ± 0.13* 3.1 ± 1.6*
● 
RELATIVE 
VALUES 
     
LF/HF 
R 1.4 ± 1.0 1.4 ± 0.8 1.8 ± 0.9 0.5 ± 0.3 
E 4.1 ± 2.0 4.0 ± 2.0 4.0 ± 2.6 0.3 ± 0.1*● 
LFnu (%) 
R 46.8 ± 19.3 46.1 ± 14.7 57.7 ± 28.2 25.9 ± 13.8 
E 69.6 ± 16.5 65.3 ± 21.2 61.6 ± 22.7 12.7 ± 8.0*● 
HFnu (%) 
R 51.1 ± 18.3 51.1 ± 15.4 38.3 ± 26.9 62.6 ±15.6 
E 15.5 ± 8.7 17.4 ± 5.0 22.6 ± 14.4 45.5 ± 23.5*● 
 650 
Values are means ± SD. PTOT: total power. LF: low frequency power. HF: high frequency 651 
power. LF/HF: low–to–high frequency ratio; LFnu, relative low frequency power; HFnu, 652 
relative high frequency power. R: Rest. E: Exercise. 653 
N=7; 2-way ANOVA for repeated measurements; p<0.05; *: significantly different from 654 
Control. ●: significantly different from Metoprolol. : significantly different from Atropine. In 655 
bold: Exercise significantly different from Rest   656 
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Table 3: Parameters resulting from the analysis of spontaneous variability of systolic and 657 
diastolic arterial pressures in the four investigated conditions: Control, Atropine, Metoprolol, 658 
and Double Blockade. 659 
SAP variability  Control Metoprolol Atropine Double Blockade 
PTOT (ms2Hz
-1) 
R 25.70 ± 11.52 26.91 ± 15.50 16.99 ± 17.77 15.63 ± 8.19 
E 70.83 ± 41.42 29.07 ± 12.24* 28.09 ± 6.77* 17.46 ± 7.00* 
LF (ms2Hz-1) 
R 7.03 ± 3.60 4.96 ± 1.90 1.55 ± 0.64*
● 2.09 ± 1.38*● 
E 18.68 ± 17.97 5.51 ± 1.52 10.93 ± 6.15*
● 5.80 ± 2.90*
 
HF (ms2Hz-1) 
R 4.04 ± 3.21 2.57 ± 1.79 1.20 ± 0.45* 1.09 ± 0.67* 
E 5.49 ± 4.20 5.48 ± 3.96 3.29 ± 1.80 2.48 ± 0.93 
LF/HF 
R 2.27 ± 1.07 2.36 ± 1.09 1.46 ± 0.70 2.32 ± 1.54 
E 2.61 ± 1.39 1.87 ± 1.32 3.46 ± 2.39 2.17 ± 0.67 
      
DAP variability      
PTOT (ms2Hz
-1) 
R 9.65 ± 6.06 9.01 ± 3.47 4.64 ± 3.03 5.10 ± 2.32 
E 7.63 ± 2.56 5.52 ± 2.56 3.92 ± 1.00 4.90 ± 3.40 
LF (ms2Hz-1) 
R 3.54 ± 2.57 2.56 ± 1.17 0.77 ± 0.52* 0.97 ± 0.67* 
E 2.70 ± 1.80 1.97 ± 0.86 1.63 ± 0.48 1.11 ± 0.31 
HF (ms2Hz-1) 
R 2.22 ± 2.77 1.88 ± 2.10 0.40 ± 0.20 0.46 ± 0.52 
E 1.66 ± 1.25 1.13 ± 0.75 0.89 ± 0.52 0.92 ± 0.50 
LF/HF 
R 3.65 ± 1.26 2.40 ± 1.21* 2.03 ± 1.26* 3.03 ± 1.48* 
E 3.00 ± 2.53 1.69 ± 0.98 2.05 ± 0.73 1.53 ± 0.63 
 660 
Values are means ± SD. PTOT: total power. LF: low frequency power. HF: high frequency 661 
power. LF/HF: low–to–high frequency ratio. R: Rest. E: Exercise. 662 
N=7; 2-way ANOVA for repeated measurements; p<0.05; *: significantly different from 663 
Control. ●: significantly different from Metoprolol; : significantly different from Atropine. In 664 
bold: Exercise significantly different from Rest   665 
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Figure 1: Heart Rate Variability (HRV) spectrum resulting from the experiments which the 666 
shown HRV segments belong to left column: Rest; right column: Exercise; first row: Control; 667 
second row: Atropine; third row: Metoprolol; fourth row: Double blockade. N=7; X axis: 668 
frequency (Hz). Y axis: RR power (ms2/Hz). Note: differences in Y scales. C: Control. A: 669 
Atropine. M: Metoprolol DB: Double blockade. 670 
Figure 2: Mean values ± SD of BRS in each investigated condition (control / atropine / 671 
metoprolol / double blockade) at rest and during exercise. BRS: Spontaneous baroreflex 672 
sensitivity. N=7; 2-way ANOVA for repeated measurements; p<0.05: *: significantly different 673 
from CTRL. #: significantly different from DB. §: significantly different from ATR. $: 674 
significantly different from the same condition at rest. 675 
 676 
Downloaded from www.physiology.org/journal/jappl by Alessandra Adami (131.128.072.082) on October 13, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Downloaded from www.physiology.org/journal/jappl by Alessandra Adami (131.128.072.082) on October 13, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Downloaded from www.physiology.org/journal/jappl by Alessandra Adami (131.128.072.082) on October 13, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
